Tracer library / [177Lu]Lu-BCY18469

[177Lu]Lu-BCY18469

Also written as [Lu-177]Lu-BCY18469

Radionuclide: Lu-177 t½ 9584.6 min
Modality: Therapy
Production route: —
Stage: Preclinical
Syntheses indexed: 1

Preclinical only, no clinical indication yet

What it is

Compound class: EphA2-targeting bicyclic peptide (Bicycle®)
Target / mechanism: EphA2 (erythropoietin-producing hepatocellular receptor A2) PMID 39239524
Clinical application: Tumors overexpressing EphA2, proposed for theranostic applications PMID 39239524
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	none	—	≥98%	BCY18469	39239524 2024 Theranostics radiolabeling with 177Lu was performed by mixing 50 µL of NH4OAc buffer

Need this precursor?We can point you to suppliers for [177Lu]Lu-BCY18469, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 39239524. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 39239524: 'BCY18469 and BCY26443 were synthesized using solid phase peptide synthesis'. Stage set/updated at stage 23 from PMID 39239524: 'This study presents the development and comprehensive in vitro and in vivo preclinical evaluation of BCY18469, a novel EphA2-targeting bicyclic peptide-based radiotheranostic agent.'.